Zenith Health Care Ltd
Incorporated in 1993, Zenith Health
care Ltd is engaged in manufacturing
and trading of pharma products[1]
- Market Cap ₹ 16.6 Cr.
- Current Price ₹ 3.08
- High / Low ₹ 4.99 / 2.23
- Stock P/E 103
- Book Value ₹ 1.38
- Dividend Yield 0.00 %
- ROCE 0.27 %
- ROE 0.13 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -5.20% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 0.77% over last 3 years.
- Working capital days have increased from 84.2 days to 122 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 11.33 | 10.52 | 10.80 | |
| 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.23 | 11.24 | 10.65 | 10.64 | |
| Operating Profit | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.24 | 0.09 | -0.13 | 0.16 |
| OPM % | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.66% | 0.79% | -1.24% | 1.48% |
| 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.26 | 0.43 | 0.41 | 0.32 | |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.23 | 0.26 | 0.26 |
| Profit before tax | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.28 | 0.01 | 0.22 |
| Tax % | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | 78.57% | 200.00% | |
| -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.07 | 0.01 | 0.16 | |
| EPS in Rs | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.01 | 0.00 | 0.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -5% |
| 3 Years: | -7% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -53% |
| 3 Years: | -50% |
| TTM: | 245% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | -16% |
| 3 Years: | -7% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| Reserves | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.03 | 2.05 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.56 | 3.48 | 3.56 | |
| Total Liabilities | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.98 |
| 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.55 | 1.45 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.49 | 9.33 | 9.52 | |
| Total Assets | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.98 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | 0.55 | -0.83 | |
| -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -1.88 | -0.96 | 0.85 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | |
| Net Cash Flow | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | -0.14 | -0.41 | 0.01 |
| Free Cash Flow | -0.18 | 0.11 | 0.11 | 0.00 | -0.11 | 1.45 | -1.66 | 1.08 | -0.95 | 1.63 | 0.16 | -0.99 |
| CFO/OP | -475% | -100% | 383% | 0% | -15% | 356% | -372% | 333% | -2,967% | 796% | 667% | 615% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 57.26 | 77.96 | 72.51 |
| Inventory Days | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 86.65 | 152.87 | 220.21 |
| Days Payable | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 38.08 | 92.93 | 115.38 |
| Cash Conversion Cycle | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 105.84 | 137.90 | 177.34 |
| Working Capital Days | 246.68 | 208.87 | 136.40 | 82.13 | 96.17 | 48.14 | 98.02 | 50.93 | 116.76 | 60.54 | 69.91 | 122.13 |
| ROCE % | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% | 3.12% | 0.27% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Export Revenue Share (% of total revenue) % |
|
|||||||||
| Manufactured Goods Share of Direct Cost % |
||||||||||
| Number of Countries with Plant Registrations count |
||||||||||
| Capital Expenditure (Purchase of fixed assets) INR Lakhs |
||||||||||
| Number of Permanent Employees count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement for Financial result of quarter ended June 30, 2026
- Submission Of Financial Results For Quarter Ended June 30, 2026
-
Board Meeting Outcome for Outcome Of The Meeting Of Board Held On 14Th August, 2026
- Board approved unaudited Q1 FY2026-27 financial results on 14 August 2026.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday, August 14, 2026
- Board meeting on 14 August 2026 to approve Q1 FY2026-27 unaudited results; trading window remains closed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement for 32nd AGM, e-voting and Book Closure.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2][3]
ZHL is in the business of manufacturing pharmaceutical formulations in the forms of general and beta lactum Tablets, Capsules, Oral liquid, and Injectables. The company offers contract manufacturing of all dosage forms.
The services include purchasing of raw materials, production, packaging, and quality control, and offering solid dosage forms in General and Beta-Lactam Tablets, Capsules, Oral Liquids, and Dry Powder Oral Suspension.